- Active not recruitingPHASE2
A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer
This study is testing a new combination of treatments, abemaciclib and tamoxifen, or abemaciclib alone, for women with advanced breast cancer that has spread. It aims to see if these treatments are safe and effective for patients who have already had previous therapies.
For: Metastatic Breast CancerUnited States · Argentina · Austria - RecruitingPHASE2
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
This study is testing a new medicine, MK-5684, for breast, ovarian, and endometrial cancers. It aims to see if MK-5684, which blocks steroid hormones, can stop cancer from growing or spreading for longer than current standard treatments.
For: Malignant NeoplasmUnited States · Argentina · Brazil - Active not recruitingPHASE3
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
This study is looking at a new drug, camizestrant, for people with a common type of early breast cancer. It aims to see if camizestrant, compared to usual hormone therapy, can better prevent the cancer from coming back.
For: Breast Cancer, Early Breast CancerUnited States · Argentina · Australia - Not yet recruitingPHASE2
Clinical Trial to Observe the Effects of Tamoxifen on Testosterone Recovery in Medically Castrated Prostate Cancer Patients
This study looks at whether a medicine called Tamoxifen can help men with prostate cancer recover their natural testosterone levels faster after they’ve had prostate cancer treatment that lowers hormones. It aims to improve their quality of life.
For: Hypogonadism · Prostate CancerCanada - Active not recruitingPHASE3
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
This study looks at whether fezolinetant can reduce hot flashes in women with breast cancer who are having hormone therapy. These hot flashes are a common side effect, and current treatments like HRT aren't suitable. We want to see if fezolinetant helps more than a dummy pill.
For: Hot FlashesCanada · Czechia · Denmark - RecruitingPHASE3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
This study is testing a new drug, Elacestrant, against standard hormone treatments for early breast cancer. It's for men and women whose cancer is ER-positive and HER2-negative, and has a high chance of coming back. The aim is to see if Elacestrant works better.
For: Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE2
Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.
This study looks at new ways to treat a type of breast cancer called HER2-positive. We're testing if using special drugs (Herceptin and Perjeta) without chemotherapy first can shrink tumours effectively. We're also checking if scans can predict how well treatments work.
For: Breast CancerBelgium · France · Germany - AuthorisedTherapeutic use (Phase IV)
ENDO-67 project: Investigating ENDOcrine therapy-related questions using Ki67 changes in the window-of-opportunity before breast surgery
This study is looking at how a common breast cancer drug, tamoxifen, works in the body. Researchers want to understand if different levels of a substance called endoxifen affect a patient's response to tamoxifen treatment before surgery, using a marker called Ki67.
For: Breast cancerNetherlands - RecruitingPHASE2
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
This study looks for tiny traces of cancer DNA in the blood to find early signs of breast cancer coming back. If found, it tests if a new treatment combination (Palbociclib and Fulvestrant) works better than standard treatment for ER-positive, HER2-negative breast cancer.
For: ER+ Breast Cancer · HER2-negative Breast CancerFrance · United Kingdom - RecruitingPHASE3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
This study is testing a new drug, camizestrant, for early breast cancer that's hormone-sensitive. We want to see if it works better than standard hormone therapy in reducing the risk of cancer coming back, for people who have already had initial treatment.
For: Breast Cancer, Early Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
This study looks at a new drug, imlunestrant, for early breast cancer. It compares it to standard hormone treatments like tamoxifen, anastrozole, letrozole, and exemestane. The goal is to see if imlunestrant works better for patients whose cancer is at higher risk of returning.
For: Breast NeoplasmsUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
This study looks at a new drug, giredestrant, with an existing drug, everolimus, for advanced breast cancer. It compares this combination to standard hormone therapy plus everolimus, for people whose cancer has grown despite previous treatments.
For: Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerUnited States · Argentina · Germany